Entia Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Sherwood, Oregon. The company went IPO on 2007-11-01. The firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases. The firm's ErgoD2 formulations utilize organically cultivated specialty mushrooms available from various domestic and international suppliers. These mushroom-based products are generally regarded as safe (GRAS). The firm's market and scientific research has identified mushroom species and suppliers to provide the nutritional profiles for its ErgoD2 formulations.
Entia Biosciences Inc 주요 수익원은 International Insurance이며, 최신 수익 발표에서 수익은 175,659,000입니다. 지역별로는 United States이 Entia Biosciences Inc의 주요 시장이며, 수익은 69,019,000입니다.
Entia Biosciences Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Entia Biosciences Inc의 순손실은 $0입니다.